Tenaya Therapeutics Inc (TNYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $79.59M
Last updated: Nov 17, 2026 at 11:05 AM ET
Tenaya Therapeutics Inc (TNYA) Stock Forecast
Analysts expect Tenaya Therapeutics (TNYA) to earn -$0.44 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.84M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 33.3% |
| Buy | 4 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 19.3%.
- Fiscal year ending Dec 31, 2026
- -$0.44
- EPS consensus, revenue $3.84M
- Fiscal year ending Dec 31, 2027
- -$0.36
- EPS consensus, revenue $3.10M
- Next report
- Mar 4, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.44 | -$0.47 to -$0.40 | 3 | $3.84M | $3.00M to $5.00M | 4 |
| Dec 31, 2027 | -$0.36 | -$0.47 to -$0.28 | 4 | $3.10M | N/A | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.09 for the quarter ending Dec 31, 2026 to -$0.08 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.10 to -$0.07 | 8 | $2.67M | N/A | 6 |
| Mar 31, 2027 | -$0.08 | -$0.09 to -$0.07 | 3 | $550000 | N/A | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.46.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.44 | -$0.42 | -$0.42 | -$0.46 | -$0.46 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.36 | -$0.39 | -$0.39 | -$0.39 | -$0.39 | N/A |
| Quarter ending Mar 31, 2027 | -$0.08 | -$0.10 | -$0.10 | -$0.10 | -$0.10 | N/A |
Frequently Asked Questions About TNYA
What is the TNYA stock forecast?
Consensus analyst estimates put Tenaya Therapeutics's EPS at -$0.44 for the fiscal year ending Dec 31, 2026, on revenue of $3.84M. The consensus rating from 6 analysts is Buy.
How do analysts rate TNYA stock?
Of 6 analysts covering Tenaya Therapeutics, 2 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TNYA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.44, with estimates from -$0.47 to -$0.40 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.36, with estimates from -$0.47 to -$0.28 from 4 analysts.
What revenue do analysts expect from Tenaya Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.84M, with estimates from $3.00M to $5.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.10M.
How many analysts cover TNYA?
6 analysts rate Tenaya Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TNYA pages: Overview, Earnings, Forecast, Financials, Competitors